

**2023**

Greenwald MK, Wiest KL, Haight BR, Laffont CM, Zhao Y. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder. *Harm Reduct J*. 2023 Dec 2;20(1):173. doi: 10.1186/s12954-023-00906-7.

Rutrick D, Learned SM, Boyett B, Hassman D, Shinde S, Zhao Y. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies. *J Subst Use Addict Treat*. 2023 Nov;154:209155. doi: 10.1016/j.josat.2023.209155.

Lee K, Zhao Y, Merali T, Fraser C, Kozicky JM, Mormont MC, Conway B. Real-world evidence for impact of opioid agonist therapy on nonfatal overdose in patients with opioid use disorder during the COVID-19 Pandemic. *J Addict Med*. 2023 Nov-Dec 01;17(6):e374-e381. Errata 2024 Mar 13. doi: 10.1097/ADM.0000000000001213.

Craft WH, Shin H, Tegge AN, Keith DR, Athamneh LN, Stein JS, Ferreira MAR, Chilcoat HD, Le Moigne A, DeVeugh-Geiss A, Bickel WK. Long-term recovery from opioid use disorder: recovery subgroups, transition states and their association with substance use, treatment and quality of life. *Addiction*. 2023 May;118(5):890-900. doi.org/10.1111/add.16115.

Ijioma SC, Chilcoat HD, DeVeugh-Geiss AM. Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019. *J Subst Use Addict Treat*. 2023 Apr;147:208980. doi: 10.1016/j.josat.2023.208980.

Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. *Drug Alcohol Depend Rep*. 2023 Mar;6:100133. doi: 10.1016/j.dadr.2023.100133.

Marsden J, Kelleher M, Gilvarry E, Mitcheson L, Bisla J, Cape A, Cowden F, Day E, Dewhurst J, Evans R, Hardy W, Hearn A, Kelly J, Lowry N, McCusker M, Murphy C, Murray R, Myton T, Quarshie S, Vanderwaal R, Wareham A, Hughes D, Hoare Z. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. *EClinicalMedicine*. 2023 Nov 17;66:102311. doi: 10.1016/j.eclinm.2023.102311.

Ochalek TA, Ringwood KJ, Davis TT, Gal TS, Wills BK, Sabo RT, Keyser-Marcus L, Martin CE, Polak K, Cumpston KL, Moeller FG. Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series. *Drug Alcohol Depend Rep*. 2023 Mar 16;7:100144. doi: 10.1016/j.dadr.2023.100144.

Lancaster K, Gendera S, Treloar C, Rhodes T, Shahbazi J, Byrne M, Degenhardt L, Farrell M. The social, material, and temporal effects of monthly extended-release buprenorphine depot treatment for opioid dependence: An Australian qualitative study. *Contemporary Drug Problems*. 2023 Mar;50(1):105–120. doi.org/10.1177/00914509221140959.

McDonald MJ, DeVeaugh-Geiss AM, Chilcoat HD, Havens JR. Assessing motivations for nonprescribed buprenorphine use among rural Appalachian substance users. *J Addict Med*. 2023 Jan-Feb 01;17(1):95-100. doi: 10.1097/ADM.0000000000001050.

Newman AH, Xi ZX, Heidbreder C. Current perspectives on selective dopamine D<sub>3</sub> receptor antagonists/partial agonists as pharmacotherapeutics for opioid and psychostimulant use disorders. *Curr Top Behav Neurosci*. 2023;60:157-201. doi: 10.1007/7854\_2022\_347.